Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
COPENHAGEN, Denmark, Dec. 21, 2015 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that it has entered into an agreement to divest its European veterinary business, including related production facilities in the Netherlands. ALK's veterinary business specialises in the development, manufacturing and marketing of immunotherapy products for veterinary use.
The divestment is in line with ALK's ongoing efforts to simplify its business structure and accelerate the rationalisation of its product portfolio. ALK's business strategy, as outlined in the recent Q3 interim report, is to focus sales efforts on standardised and evidence-based products for human use, such as the SLIT-tablet portfolio.
The agreement with the buyer - the Swedish investment company Fidelio Capital - is final and the transaction will be effective as of 30 December 2015.
The value of the transaction is undisclosed, however, the divestment is expected to impact ALK's full-year guidance on free cash flow positively by DKK 40-50 million. The divestment does not materially impact ALK's full-year guidance for revenue and EBITDA before special items. The net gain on the sale will be recognised as special items in the profit and loss statement.
Kempen & Co acted as exclusive M&A advisor to ALK.
ALK's European veterinary business was expected to have revenue of approximately DKK 30 million for 2015. The business employs 25 people.
ALK-Abello A/S
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjaer, tel. +45 7877 4532, mobile +45 3050 2014
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy - a treatment of the underlying cause of allergy. The company has approximately 1,900 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and Seqirus (previously bioCSL) to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, and Australia and New Zealand, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.
